Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
Authors:
- 21 July 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (27) , 8898-909
Abstract
Irritable bowel syndrome (IBS) is a highly prevalent medical condition that adversely affects patient quality of life and constitutes a significant economic burden on healthcare resources. A large proportion of patients suffer from the constipation subtype of IBS (IBS-C), most commonly afflicting older individuals and those with a lower socioeconomic status. Conventional pharmacologic and nonpharmacologic treatment options have limited efficacies and/or significant adverse events, which lead to increased long-term health care expenditures. Failure to effectively treat IBS-C patients over the past decades has largely been due to a poor understanding of disease pathophysiology, lack of a global view of the patient, and an inappropriate selection of patients and treatment endpoints in clinical trials. In recent years, however, more effective and safer drugs have been developed for the treatment of IBS-C. The advancement in the area of pharmacologic treatment is based on new knowledge of the pathophysiologic basis of IBS-C and the development of drugs with increased selectivity within pharmacologic classes with recognized efficacies. This narrative review covers the spectrum of available drugs and their mechanisms of action, as well as the efficacy and safety profiles of each as determined in relevant clinical trials that have investigated treatment options for IBS-C and chronic constipation. A brief summary of laxative-based treatment options is presented, followed by up-to-date assessments for three classes of drugs: prokinetics, prosecretory agents, and bile acid modulators.Keywords
This publication has 83 references indexed in Scilit:
- Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burdenJournal of Medical Economics, 2012
- A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic ConstipationAmerican Journal of Gastroenterology, 2011
- Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind studyAlimentary Pharmacology & Therapeutics, 2011
- Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response studyAlimentary Pharmacology & Therapeutics, 2010
- A multinational survey of prevalence and patterns of laxative use among adults with self‐defined constipationAlimentary Pharmacology & Therapeutics, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Effect of 5 Days Linaclotide on Transit and Bowel Function in Females With Constipation-Predominant Irritable Bowel SyndromeGastroenterology, 2007
- Diversity of Cl− ChannelsCellular and Molecular Life Sciences, 2005
- Treatment of Constipation with Chenodeoxycholic AcidJournal of International Medical Research, 1983
- Effects of Chenodeoxy- and Ursodeoxycholic Acid on Absorption, Secretion and Permeability in Rat Colon and Small IntestineDigestion, 1980